Results 151 to 160 of about 114,702 (262)

Management of cardiovascular complications of bruton tyrosine kinase inhibitors [PDF]

British Journal of Haematology, 2021
Chloe Pek Sang Tang, Gregory Y.H. Lip, Terry McCormack, Alexander R. Lyon, Peter Hillmen, Sunil Iyengar, Nicolas Martinez‐Calle, Nilima Parry‐Jones, Piers E.M. Patten, Anna Schuh, Renata Walewska   +10 more
openaire   +4 more sources

Functional interaction between CD180 Toll-like receptor (TLR) and B cell receptor (BCR) in the biology of Chronic Lymphocytic Leukaemia (CLL) [PDF]

, 2017
Chronic Lymphocytic Leukaemia (CLL) is the most common leukaemia in the western world and remains incurable. It is driven by as yet unknown (auto)antigens via the B cell receptor (BCR) and growth, survival and expansion signals it receives from the ...
Rajakaruna, A., Rajakaruna, A.
core  

Ibrutinib alternating with three cycles of interval fludarabine, cyclophosphamide, and rituximab (FCR) in adults with untreated chronic lymphocytic leukaemia as time-limited regimen: a single-arm, multicentre phase 2 trial in ChinaResearch in context

EClinicalMedicine
Summary: Background: Effective time-limited therapies remain an unmet need in chronic lymphocytic leukaemia (CLL). We evaluated a novel regimen combining ibrutinib with intermittent fludarabine, cyclophosphamide, and rituximab (FCR) in patients with CLL.
Tingyu Wang, Yuting Yan, Hui Wang, Ying Sun, Xiantao Liu, Rui Lyu, Wenjie Xiong, Gang An, Wei Liu, Yan Xu, Shuhui Deng, Qi Wang, Chenxing Du, Liang Huang, Dehui Zou, Yaozhong Zhao, Lugui Qiu, Zengjun Li, Shuhua Yi   +18 more
doaj   +1 more source

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy

Proceedings of the National Academy of Sciences of the United States of America, 2010
L. Honigberg, Ashley M. Smith, M. Sirisawad, E. Verner, D. Loury, B. Chang, Shyr-Jiann Li, Z. Pan, D. Thamm, Richard A. Miller, J. Buggy   +10 more
semanticscholar   +1 more source

Proliferation tracing with single-cell mass cytometry optimizes generation of stem cell memory-like T cells. [PDF]

, 2019
Selective differentiation of naive T cells into multipotent T cells is of great interest clinically for the generation of cell-based cancer immunotherapies. Cellular differentiation depends crucially on division state and time.
Bendall, Sean C, Borges, Luciene, Good, Zinaida, Nolan, Garry P, Sahaf, Bita, Samusik, Nikolay, Tibshirani, Robert, Vivanco Gonzalez, Nora   +7 more
core  

Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.

Journal of Clinical Oncology, 2013
R. Advani, J. Buggy, J. Sharman, Sonali M. Smith, T. Boyd, B. Grant, K. Kolibaba, R. Furman, S. Rodríguez, B. Chang, J. Sukbuntherng, R. Izumi, A. Hamdy, E. Hedrick, N. Fowler   +14 more
semanticscholar   +1 more source

Preventing and managing the toxicities associated with the combination therapy of ibrutinib and venetoclax in chronic lymphocytic leukaemia

Acta Haematologica Polonica
The combination of ibrutinib and venetoclax represents the first fixed-duration oral treatment involving a Bruton tyrosine kinase inhibitor and a BCL2 inhibitor for adult patients with untreated chronic lymphocytic leukaemia.
Elżbieta Iskierka-Jażdżewska, Krzysztof Jamroziak, Tadeusz Robak, Bartosz Puła   +3 more
doaj   +1 more source

A Support Vector Machine Base Model for Predicting Heparin-Binding Proteins Using Biological Metrics and XB Patterns as Features [PDF]

, 2016
Heparin is a highly sulphated and negatively charged polysaccharides belonging to the glycosamino- glycans(GAGs) family. It is widely used in medical treatments as an injectable anticoagulant.
Sirrianni, Joseph W
core   +1 more source

Rituximab combined with Bruton tyrosine kinase inhibitor to treat elderly diffuse large B-cell lymphoma patients: Two case reports. [PDF]

World J Clin Cases, 2023
Zhang CJ, Zhao ML.
europepmc   +1 more source

Efficacy and safety of add-on anti-CD20 monoclonal antibody to Bruton tyrosine kinase inhibitor treatment for chronic lymphocytic leukemia: a meta-analysis. [PDF]

Sci Rep, 2023
Nguyen TT, Nhu NT, Tran VK, Viet-Nhi NK, Ho XD, Jhan MK, Chen YP, Lin CF.   +7 more
europepmc   +1 more source